Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Breast milk prefusion F IgG as a correlate of protection against respiratory syncytial virus acute respiratory illness.

Mazur NI, Horsley N, Englund JA, Nederend M, Magaret A, Kumar A, Jacobino SR, Xander H, Khatry SK, LeClerq SC, Steinhoff MC, Tielsch JM, Katz J, Graham BS, Bont LJ, Leusen JHW, Chu HY.

J Infect Dis. 2018 Aug 10. doi: 10.1093/infdis/jiy477. [Epub ahead of print]

PMID:
30107412
2.

The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.

Evers M, Jak M, Leusen JHW.

Expert Opin Biol Ther. 2018 Aug 10:1-10. doi: 10.1080/14712598.2018.1508444. [Epub ahead of print]

PMID:
30084674
3.

Mechanisms of inside-out signaling of the high-affinity IgG receptor FcγRI.

Brandsma AM, Schwartz SL, Wester MJ, Valley CC, Blezer GLA, Vidarsson G, Lidke KA, Ten Broeke T, Lidke DS, Leusen JHW.

Sci Signal. 2018 Jul 24;11(540). pii: eaaq0891. doi: 10.1126/scisignal.aaq0891.

PMID:
30042128
4.

Effects of Bovine Immunoglobulins on Immune Function, Allergy, and Infection.

Ulfman LH, Leusen JHW, Savelkoul HFJ, Warner JO, van Neerven RJJ.

Front Nutr. 2018 Jun 22;5:52. doi: 10.3389/fnut.2018.00052. eCollection 2018. Review.

5.

Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis.

Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, Franke K, Schornagel K, Verkuijlen P, Janssen H, Halonen P, Lieftink C, Beijersbergen RL, Leusen JHW, Boelens JJ, Kuhnle I, van der Werff Ten Bosch J, Seeger K, Rutella S, Pagliara D, Matozaki T, Suzuki E, Menke-van der Houven van Oordt CW, van Bruggen R, Roos D, van Lier RAW, Kuijpers TW, Kubes P, van den Berg TK.

Cell Rep. 2018 Jun 26;23(13):3946-3959.e6. doi: 10.1016/j.celrep.2018.05.082.

6.

Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells".

Evers M, Kruse E, Hamdan F, Lebbink RJ, Leusen JHW.

J Immunol. 2018 Apr 15;200(8):2515-2516. doi: 10.4049/jimmunol.1800087. No abstract available.

PMID:
29632250
7.

Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo.

Jacobino SR, Nederend M, Reijneveld JF, Augustijn D, Jansen JHM, Meeldijk J, Reiding KR, Wuhrer M, Coenjaerts FEJ, Hack CE, Bont LJ, Leusen JHW.

MAbs. 2018 Apr;10(3):453-462. doi: 10.1080/19420862.2018.1433974. Epub 2018 Mar 19.

8.

New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies.

Meyer S, Evers M, Jansen JHM, Buijs J, Broek B, Reitsma SE, Moerer P, Amini M, Kretschmer A, Ten Broeke T, den Hartog MT, Rijke M, Klein C, Valerius T, Boross P, Leusen JHW.

Br J Haematol. 2018 Mar;180(6):808-820. doi: 10.1111/bjh.15132. Epub 2018 Feb 22.

PMID:
29468712
9.

Single Nucleotide Polymorphisms of the High Affinity IgG Receptor FcγRI Reduce Immune Complex Binding and Downstream Effector Functions.

Brandsma AM, Ten Broeke T, van Dueren den Hollander E, Caniels TG, Kardol-Hoefnagel T, Kuball J, Leusen JHW.

J Immunol. 2017 Oct 1;199(7):2432-2439. doi: 10.4049/jimmunol.1601929. Epub 2017 Aug 16.

PMID:
28814603
10.

Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.

Lohse S, Loew S, Kretschmer A, Jansen JHM, Meyer S, Ten Broeke T, Rösner T, Dechant M, Derer S, Klausz K, Kellner C, Schwanbeck R, French RR, Tipton TRW, Cragg MS, Schewe DM, Peipp M, Leusen JHW, Valerius T.

Br J Haematol. 2018 May;181(3):413-417. doi: 10.1111/bjh.14624. Epub 2017 Apr 27. No abstract available.

PMID:
28449349
11.

DC subset-specific induction of T cell responses upon antigen uptake via Fcγ receptors in vivo.

Lehmann CHK, Baranska A, Heidkamp GF, Heger L, Neubert K, Lühr JJ, Hoffmann A, Reimer KC, Brückner C, Beck S, Seeling M, Kießling M, Soulat D, Krug AB, Ravetch JV, Leusen JHW, Nimmerjahn F, Dudziak D.

J Exp Med. 2017 May 1;214(5):1509-1528. doi: 10.1084/jem.20160951. Epub 2017 Apr 7.

12.

MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL.

Vikström IB, Slomp A, Carrington EM, Moesbergen LM, Chang C, Kelly GL, Glaser SP, Jansen JH, Leusen JH, Strasser A, Huang DC, Lew AM, Peperzak V, Tarlinton DM.

Cell Death Dis. 2016 Aug 25;7(8):e2345. doi: 10.1038/cddis.2016.237.

13.

Clarifying the Confusion between Cytokine and Fc Receptor "Common Gamma Chain".

Brandsma AM, Hogarth PM, Nimmerjahn F, Leusen JH.

Immunity. 2016 Aug 16;45(2):225-6. doi: 10.1016/j.immuni.2016.07.006. No abstract available.

14.

Human amniotic fluid antibodies protect the neonate against respiratory syncytial virus infection.

Jacobino SR, Nederend M, Hennus M, Houben ML, Ngwuta JO, Viveen M, Coenjaerts FEJ, Hack CE, van Neerven RJJ, Graham BS, Bont L, Leusen JHW.

J Allergy Clin Immunol. 2016 Nov;138(5):1477-1480.e5. doi: 10.1016/j.jaci.2016.06.001. Epub 2016 Jun 16. No abstract available.

PMID:
27448445
15.

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.

Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren JJ, Groen RW, Parren PW, Leusen JH, Boross P.

J Immunol. 2016 Aug 1;197(3):807-13. doi: 10.4049/jimmunol.1501351. Epub 2016 Jun 17.

16.

Intravenous immune globulin suppresses angiogenesis in mice and humans.

Yasuma R, Cicatiello V, Mizutani T, Tudisco L, Kim Y, Tarallo V, Bogdanovich S, Hirano Y, Kerur N, Li S, Yasuma T, Fowler BJ, Wright CB, Apicella I, Greco A, Brunetti A, Ambati BK, Helmers SB, Lundberg IE, Viklicky O, Leusen JH, Verbeek JS, Gelfand BD, Bastos-Carvalho A, De Falco S, Ambati J.

Signal Transduct Target Ther. 2016;1. pii: 15002. Epub 2016 Jan 28.

17.

Human IgG1 antibodies suppress angiogenesis in a target-independent manner.

Bogdanovich S, Kim Y, Mizutani T, Yasuma R, Tudisco L, Cicatiello V, Bastos-Carvalho A, Kerur N, Hirano Y, Baffi JZ, Tarallo V, Li S, Yasuma T, Arpitha P, Fowler BJ, Wright CB, Apicella I, Greco A, Brunetti A, Ruvo M, Sandomenico A, Nozaki M, Ijima R, Kaneko H, Ogura Y, Terasaki H, Ambati BK, Leusen JH, Langdon WY, Clark MR, Armour KL, Bruhns P, Verbeek JS, Gelfand BD, De Falco S, Ambati J.

Signal Transduct Target Ther. 2016;1. pii: 15001. Epub 2016 Jan 28.

18.

An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo.

Lohse S, Meyer S, Meulenbroek LA, Jansen JH, Nederend M, Kretschmer A, Klausz K, Möginger U, Derer S, Rösner T, Kellner C, Schewe D, Sondermann P, Tiwari S, Kolarich D, Peipp M, Leusen JH, Valerius T.

Cancer Res. 2016 Jan 15;76(2):403-17. doi: 10.1158/0008-5472.CAN-15-1232. Epub 2015 Dec 3.

19.

IgA as therapeutic antibody.

Leusen JH.

Mol Immunol. 2015 Nov;68(1):35-9. doi: 10.1016/j.molimm.2015.09.005. Review.

PMID:
26597204
20.

Fc receptor inside-out signaling and possible impact on antibody therapy.

Brandsma AM, Jacobino SR, Meyer S, ten Broeke T, Leusen JH.

Immunol Rev. 2015 Nov;268(1):74-87. doi: 10.1111/imr.12332. Review.

PMID:
26497514
21.

Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting.

Meyer S, Nederend M, Jansen JH, Reiding KR, Jacobino SR, Meeldijk J, Bovenschen N, Wuhrer M, Valerius T, Ubink R, Boross P, Rouwendal G, Leusen JH.

MAbs. 2016;8(1):87-98. doi: 10.1080/19420862.2015.1106658. Epub 2015 Oct 14. Erratum in: MAbs. 2017 Jan;9(1):165.

22.

A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA.

Rouwendal GJ, van der Lee MM, Meyer S, Reiding KR, Schouten J, de Roo G, Egging DF, Leusen JH, Boross P, Wuhrer M, Verheijden GF, Dokter WH, Timmers M, Ubink R.

MAbs. 2016;8(1):74-86. doi: 10.1080/19420862.2015.1102812. Epub 2015 Oct 6.

23.

Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.

Brandsma AM, Ten Broeke T, Nederend M, Meulenbroek LA, van Tetering G, Meyer S, Jansen JH, Beltrán Buitrago MA, Nagelkerke SQ, Németh I, Ubink R, Rouwendal G, Lohse S, Valerius T, Leusen JH, Boross P.

Cancer Immunol Res. 2015 Dec;3(12):1316-24. doi: 10.1158/2326-6066.CIR-15-0099-T. Epub 2015 Sep 25.

24.

Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics.

Widjaja I, Rigter A, Jacobino S, van Kuppeveld FJ, Leenhouts K, Palomo C, Melero JA, Leusen JH, Haijema BJ, Rottier PJ, de Haan CA.

PLoS One. 2015 Jun 24;10(6):e0130829. doi: 10.1371/journal.pone.0130829. eCollection 2015.

25.

Targeted delivery of a sialic acid-blocking glycomimetic to cancer cells inhibits metastatic spread.

Büll C, Boltje TJ, van Dinther EA, Peters T, de Graaf AM, Leusen JH, Kreutz M, Figdor CG, den Brok MH, Adema GJ.

ACS Nano. 2015 Jan 27;9(1):733-45. doi: 10.1021/nn5061964. Epub 2015 Jan 14.

PMID:
25575241
26.

Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.

Winiarska M, Bojarczuk K, Pyrzynska B, Bil J, Siernicka M, Dwojak M, Bobrowicz M, Miazek N, Zapala P, Zagozdzon A, Krol M, Syta A, Podszywalow-Bartnicka P, Pilch Z, Dabrowska-Iwanicka A, Juszczynski P, Efremov DG, Slabicki M, Zenz T, Le Roy A, Olive D, Rygiel TP, Leusen JH, Golab J.

MAbs. 2014;6(5):1300-13. doi: 10.4161/mabs.32106. Epub 2014 Oct 30.

27.

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.

Meyer S, Leusen JH, Boross P.

MAbs. 2014;6(5):1133-44. doi: 10.4161/mabs.29670. Epub 2014 Oct 30. Review.

28.

Specificity and Effector Functions of Human RSV-Specific IgG from Bovine Milk.

den Hartog G, Jacobino S, Bont L, Cox L, Ulfman LH, Leusen JH, van Neerven RJ.

PLoS One. 2014 Nov 6;9(11):e112047. doi: 10.1371/journal.pone.0112047. eCollection 2014.

29.

FcRγ-chain ITAM signaling is critically required for cross-presentation of soluble antibody-antigen complexes by dendritic cells.

Boross P, van Montfoort N, Stapels DA, van der Poel CE, Bertens C, Meeldijk J, Jansen JH, Verbeek JS, Ossendorp F, Wubbolts R, Leusen JH.

J Immunol. 2014 Dec 1;193(11):5506-14. doi: 10.4049/jimmunol.1302012. Epub 2014 Oct 29.

30.

A novel FcγRIIa Q27W gene variant is associated with common variable immune deficiency through defective FcγRIIa downstream signaling.

Flinsenberg TW, Janssen WJ, Herczenik E, Boross P, Nederend M, Jongeneel LH, Scholman RC, Boelens JJ, Maas C, van Gijn ME, van Montfrans JM, Leusen JH, Boes M.

Clin Immunol. 2014 Nov;155(1):108-17. doi: 10.1016/j.clim.2014.09.006. Epub 2014 Sep 19.

PMID:
25242138
31.

Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice.

Boross P, Jansen JH, van Tetering G, Nederend M, Brandsma A, Meyer S, Torfs E, van den Ham HJ, Meulenbroek L, de Haij S, Leusen JH.

Immunol Lett. 2014 Aug;160(2):151-7. doi: 10.1016/j.imlet.2014.02.005. Epub 2014 Mar 5.

PMID:
24613852
32.

Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody.

Brunke C, Lohse S, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, Royle L, Liew LP, Leusen JH, Valerius T.

MAbs. 2013 Nov-Dec;5(6):936-45. doi: 10.4161/mabs.26396.

33.

Fcγ receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy.

Stork AC, Notermans NC, van den Berg LH, Schellevis RD, Niermeijer JM, Nederend M, Leusen JH, van der Pol WL.

J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):918-20. doi: 10.1136/jnnp-2013-306958. Epub 2014 Jan 31.

PMID:
24487381
34.

Inhibition of the classical and lectin pathway of the complement system by recombinant LAIR-2.

Olde Nordkamp MJ, Boross P, Yildiz C, Jansen JH, Leusen JH, Wouters D, Urbanus RT, Hack CE, Meyaard L.

J Innate Immun. 2014;6(3):284-92. doi: 10.1159/000354976. Epub 2013 Nov 1.

PMID:
24192271
35.

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.

Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, Introna M.

Blood. 2013 Nov 14;122(20):3482-91. doi: 10.1182/blood-2013-05-504043. Epub 2013 Oct 8.

36.

IgG antibodies in food allergy influence allergen-antibody complex formation and binding to B cells: a role for complement receptors.

Meulenbroek LA, de Jong RJ, den Hartog Jager CF, Monsuur HN, Wouters D, Nauta AJ, Knippels LM, van Neerven RJ, Ruiter B, Leusen JH, Hack CE, Bruijnzeel-Koomen CA, Knulst AC, Garssen J, van Hoffen E.

J Immunol. 2013 Oct 1;191(7):3526-33. doi: 10.4049/jimmunol.1202398. Epub 2013 Aug 30.

37.

IgA EGFR antibodies mediate tumour killing in vivo.

Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N, Bleeker WK, Parren PW, van de Winkel JG, Valerius T, Leusen JH.

EMBO Mol Med. 2013 Aug;5(8):1213-26. doi: 10.1002/emmm.201201929.

38.

Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcγR antagonists that inhibit IgG-mediated effector functions.

Stemerding AM, Köhl J, Pandey MK, Kuipers A, Leusen JH, Boross P, Nederend M, Vidarsson G, Weersink AY, van de Winkel JG, van Kessel KP, van Strijp JA.

J Immunol. 2013 Jul 1;191(1):353-62. doi: 10.4049/jimmunol.1203243. Epub 2013 Jun 5.

39.

Mechanisms of action of CD20 antibodies.

Boross P, Leusen JH.

Am J Cancer Res. 2012;2(6):676-90. Epub 2012 Nov 20.

40.

Cutting edge: FcγRIII (CD16) and FcγRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma.

Albanesi M, Mancardi DA, Macdonald LE, Iannascoli B, Zitvogel L, Murphy AJ, Daëron M, Leusen JH, Bruhns P.

J Immunol. 2012 Dec 15;189(12):5513-7. doi: 10.4049/jimmunol.1201511. Epub 2012 Nov 12. Erratum in: J Immunol. 2013 Feb 1;190(3):1381. Daëron, Marc [added].

41.

Immunoreceptors: evolution, structure and therapeutic applications.

Leusen JH.

EMBO Rep. 2012 Dec;13(12):1046-8. doi: 10.1038/embor.2012.179. Epub 2012 Nov 13.

42.

Crosstalk between human IgG isotypes and murine effector cells.

Overdijk MB, Verploegen S, Ortiz Buijsse A, Vink T, Leusen JH, Bleeker WK, Parren PW.

J Immunol. 2012 Oct 1;189(7):3430-8. Epub 2012 Sep 5.

43.

Boosting antibody therapy with complement.

Boross P, Leusen JH.

Blood. 2012 Jun 21;119(25):5945-7. doi: 10.1182/blood-2012-04-420760.

44.

Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.

Lohse S, Brunke C, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, van der Winkel JG, Leusen JH, Valerius T.

J Biol Chem. 2012 Jul 20;287(30):25139-50. doi: 10.1074/jbc.M112.353060. Epub 2012 Jun 7.

45.

Patients with unstable angina pectoris show an increased frequency of the Fc gamma RIIa R131 allele.

Raaz-Schrauder D, Ekici AB, Munoz LE, Klinghammer L, Voll RE, Leusen JH, van de Winkel JG, Reis A, Schett G, Garlichs CD, Herrmann M.

Autoimmunity. 2012 Nov;45(7):556-64. doi: 10.3109/08916934.2012.682665. Epub 2012 Jun 20.

PMID:
22559288
46.

Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice.

Boross P, Jansen JH, Pastula A, van der Poel CE, Leusen JH.

Immunol Lett. 2012 Mar 30;143(1):44-52. doi: 10.1016/j.imlet.2012.01.004. Epub 2012 Jan 23.

PMID:
22285696
47.

Contribution of classic and alternative effector pathways in peanut-induced anaphylactic responses.

Smit JJ, Willemsen K, Hassing I, Fiechter D, Storm G, van Bloois L, Leusen JH, Pennings M, Zaiss D, Pieters RH.

PLoS One. 2011;6(12):e28917. doi: 10.1371/journal.pone.0028917. Epub 2011 Dec 14.

48.

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.

Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, Leusen JH.

Haematologica. 2011 Dec;96(12):1822-30. doi: 10.3324/haematol.2011.047159. Epub 2011 Aug 31.

49.

The Fcγ receptor IIA R131H gene polymorphism is associated with endothelial function in patients with hypercholesterolaemia.

Schneider MP, Leusen JH, Herrmann M, Garlichs CD, Amann K, John S, Schmieder RE.

Atherosclerosis. 2011 Oct;218(2):411-5. doi: 10.1016/j.atherosclerosis.2011.07.009. Epub 2011 Jul 20.

PMID:
21813128
50.

Functional characteristics of the high affinity IgG receptor, FcγRI.

van der Poel CE, Spaapen RM, van de Winkel JG, Leusen JH.

J Immunol. 2011 Mar 1;186(5):2699-704. doi: 10.4049/jimmunol.1003526. Review.

Supplemental Content

Loading ...
Support Center